Li Jia, Hong Dongsheng, Dong Jiankun, Zhao Qingwei, Wang Hongmei
Department of Pharmacy of the First Affiliated Hospital, and Department of Social Medicine of School of Public Health, Zhejiang University School of Medicine, Hangzhou, 310058, People's Republic of China.
Department of Clinical Pharmacy, Zhejiang Provincial Engineering Center for Innovative Drug Clinical Research and Application, Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China.
Clin Interv Aging. 2025 Jul 30;20:1155-1164. doi: 10.2147/CIA.S519649. eCollection 2025.
This study sought to characterize the prevalence, patterns, and associated risk factors for Potentially Inappropriate Medication use among older patients living with HIV/AIDS. The ultimate goal of this study is to inform strategies to increase medication safety in this vulnerable population.
Using the 2023 American Geriatrics Society Beers Criteria, we performed a comprehensive retrospective analysis of medication use patterns among HIV/AIDS patients aged ≥65 years, drawing data from 21 hospitals across eight Chinese cities between 2019 and 2023. The analytical framework incorporated descriptive statistics, negative binomial regression for trend analysis, and multivariable logistic regression to evaluate PIM prevalence and identify associated risk factors.
The analysis included 2,642 patients (80.28% male; median age 71 years, IQR: 6775). The PIM prevalence was 23.20% (613/2,642) in the cohort, with medications contraindicated in older adults constituting the largest category (51.87%), followed by disease-related PIMs (19.88%) and medications requiring cautious use (27.80%). Type 3 PIMs demonstrated a consistent and statistically significant downward trend throughout the study period (<0.001). Conversely, using a single PIM exhibited a statistically significant upward trajectory (=0.020). In multivariate modeling, polypharmacy emerged as the strongest predictor of PIM use (adjusted OR=9.05, 95% CI: 7.2011.38), followed by hospitalization (adjusted OR=1.38, 95% CI: 1.051.80), with consistent associations observed across the 6584 year age range (all <0.05).
The substantial and increasing burden of PIM use among elderly patients living with HIV/AIDS underscores the urgent need for enhanced medication oversight. Targeted intervention strategies should prioritize patients with polypharmacy, those requiring hospitalization, and those with specific age demographics.
本研究旨在描述感染艾滋病毒/艾滋病的老年患者中潜在不适当用药的患病率、模式及相关危险因素。本研究的最终目标是为提高这一弱势群体用药安全性的策略提供依据。
我们采用2023年美国老年医学会Beers标准,对年龄≥65岁的艾滋病毒/艾滋病患者的用药模式进行了全面回顾性分析,数据来源于2019年至2023年中国八个城市的21家医院。分析框架包括描述性统计、用于趋势分析的负二项回归以及用于评估潜在不适当用药患病率和识别相关危险因素的多变量逻辑回归。
分析纳入了2642例患者(男性占80.28%;中位年龄71岁,四分位间距:6775岁)。队列中潜在不适当用药的患病率为23.20%(613/2642),其中老年人禁忌使用的药物类别占比最大(51.87%),其次是与疾病相关的潜在不适当用药(19.88%)和需谨慎使用的药物(27.80%)。在整个研究期间,3类潜在不适当用药呈现出持续且具有统计学意义(<0.001)的下降趋势。相反,使用单一潜在不适当用药呈现出具有统计学意义(=0.020)的上升轨迹。在多变量模型中,多重用药是潜在不适当用药使用的最强预测因素(调整后的比值比=9.05,95%置信区间:7.2011.38),其次是住院治疗(调整后的比值比=1.38,95%置信区间:1.05~1.80),在65至84岁年龄范围内观察到一致的关联(均<0.05)。
感染艾滋病毒/艾滋病的老年患者中潜在不适当用药的负担沉重且不断增加,这凸显了加强用药监管的迫切需求。有针对性的干预策略应优先考虑多重用药患者、需要住院治疗的患者以及特定年龄人群。